Document Server@UHasselt >
Research publications >
Please use this identifier to cite or link to this item:
|Title: ||Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture|
|Authors: ||Driessen, Johanna H. M.|
van Onzenoort, Hein A. W.
Henry, Ronald M. A.
VAN DEN BERGH, Joop
Leufkens, Hubert G. M.
de Vries, Frank
|Issue Date: ||2014|
|Publisher: ||ELSEVIER SCIENCE INC|
|Citation: ||BONE, 68, p. 124-130|
|Abstract: ||Introduction: Although patients with type 2 diabetes mellitus have an increased bone mineral density as compared to healthy patients, their risk of fracture is elevated. Incretins, new anti-diabetic drugs, may have a protective effect on bone mineral density. However, data on the effect of incretins on fracture risk are limited. Therefore the aim of this study was to investigate the association between the use of DPP4-I and the risk of fracture. Methods: A retrospective population based cohort study, using data from the Clinical Practice Research Datalink (CPRD) database (2007-2012), was conducted. Patients (N=216,816) with at least one prescription for a non-insulin anti-diabetic drug (NIAD), aged 18+ during data collection, were matched to one control patient. Cox proportional hazards models were used to estimate the hazard ratio of any fracture in DPP4 inhibitor (DPP4-I) users versus controls and versus other NIAD patients. Time-dependent adjustments were made for age, sex, life style, comorbidity and drug use. Results: The actual duration of DPP4-I use was 1.3 years. There was no different risk of fracture comparing current DPP4-I users to controls (adjusted hazard ratio (adj.HR) 0.89,95% confidence interval (CI) 0.71-1.13). There was also no increased risk comparing current DPP4-I users to other NIAD users, adj. HR 1.03 (95% CI 0.92-1.15). Conclusions: DPP4-I use was not associated with fracture risk compared to controls and to other NIAD users. However, the duration of DPP4-I use in our database might have been too short to show an association with fracture risk. (C) 2014 Elsevier Inc. All rights reserved.|
|Notes: ||[Driessen, Johanna H. M.; Lalmohamed, Arief; Leufkens, Hubert G. M.; de Vries, Frank] Utrecht Inst Pharmaceut Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands. [Driessen, Johanna H. M.; Neef, Cees; de Vries, Frank] Care & Publ Hlth Res Inst CAPHRI, Maastricht, Netherlands. [Driessen, Johanna H. M.; van Onzenoort, Hein A. W.; Neef, Cees; de Vries, Frank] Maastricht Univ, Med Ctr, Dept Clin Pharm & Toxicol, Maastricht, Netherlands. [van Onzenoort, Hein A. W.] Radboud Univ Nijmegen, Med Ctr, Dept Pharm, NL-6525 ED Nijmegen, Netherlands. [Henry, Ronald M. A.] Maastricht Univ, Med Ctr, Dept Med, Maastricht, Netherlands. [Henry, Ronald M. A.] Maastricht Univ, Med Ctr, Cardiovasc Res Inst Maastricht, Maastricht, Netherlands. [Lalmohamed, Arief] Univ Med Ctr Utrecht, Dept Clin Pharm, Utrecht, Netherlands. [van den Bergh, Joop P.] Viecuri Med Ctr, Dept Internal Med, Venlo, Netherlands. [van den Bergh, Joop P.] Maastricht Univ, Med Ctr, Dept Internal Med, Maastricht, Netherlands. [van den Bergh, Joop P.] Univ Hasselt, Biomed Res Inst, Hasselt, Belgium. [de Vries, Frank] Southampton Gen Hosp, MRC, Epidemiol Lifecourse Unit, Southampton SO9 4XY, Hants, England.|
|ISI #: ||000343195100016|
|Type: ||Journal Contribution|
|Validation: ||ecoom, 2015|
|Appears in Collections: ||Research publications|
Files in This Item:
|published version||198.46 kB||Adobe PDF|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.